CanniMed News Banner



We are a biopharmaceutical company, which means that research is paramount to us, and so is our corporate priority to further the scientific understanding of medical cannabis.

Before the Marihuana for Medical Purposes Regulations (MMPR) came to be, our cannabis was used in a clinical trial to determine if it was in fact beneficial for pain. It was, and the results of that study helped position cannabis within the Canadian Pain Society’s consensus statement as a valuable treatment option for patients suffering from neuropathic pain symptoms.

Research takes time and a whole lot of money. With more than $1million invested to date, our Health Canada approved CAPRI Trial (Cannabinoid Profile Investigation of Vaporized Cannabis in Patients with Osteoarthritis of the Knee) is officially underway recruiting patients at the McGill University Health Centre. Recruitment will begin at the second site, Dalhousie University, shortly.

We are excited to be leading the way in this new scientific frontier.

Not only will this trial look to validate medical cannabis as a safe and effective pain relief option, it is the first clinical trial that will look at varying ratios of THC and CBC to help answer whether high THC, high CBD or a combination of the two has the greatest impact on the treatment of osteoarthritis of the knee.

If you think you might be a candidate for this study, please feel free to contact the respective clinic sites.

Brent Zettl

Press Release:

CAPRI is a Health Canada approved clinical trial looking to determine what the pain-relieving characteristics of vaporized cannabis are on patients.

The study will be recruiting patients who are 50 years or older and have primary osteoarthritis of the knee. Patients will be considered if they are on a stable medication and treatment regimen, and not currently using cannabinoids.

For more information, please contact:

McGill University Health Centre; Sylvie Toupin;; 514-934-1934 x44348

Dalhousie University; Myrna Yazer;; 902-473-7449